Corosolic acid, a triterpenoid compound widely existing in many traditional Chinese medicinal herbs, has been proved to have antidiabetic effects on animal experiments and clinical trials.
Type 2 diabetes mellitus or non-insulin-dependent diabetes mellitus is a widespread syndrome characterized by fasting and post-prandial hyperglycemia affecting increasing number of the world population. Despite considerable progress in the management of diabetes mellitus with synthetic drugs, the search for indigenous natural antidiabetic agents is ongoing. With the distinctive traditional medical opinions and natural medicines mainly originated in herbs, the traditional Chinese medicine performed a good clinical practice and is showing a bright future in the therapy of diabetes mellitus and its complications. Based on a large number of chemical and pharmacological research work, numerous bioactive compounds have been found in Chinese medicinal plants for diabetes.
Corosolic acid , a triterpenoid named 2α-hydric ursolic acid, has been discovered in many Chinese medicinal herbs, such as the Lagerstroemia speciosa L, banaba leaves,Tiarella polyphylla etc. Recently, it has been reported to have antidiabetic activity in some animal experiments and clinical trials. Miura T reported that Corosolic acid reduced the blood glucose levels and significantly lowered plasma insulin levels in KK-Ay mice 2 weeks after a single oral dose of 2 mg/ kg. Furthermore, blood glucose in KK-Ay mice treated with Corosolic acid significantly decreased in an insulin tolerance test .The muscle GLUT4 translocation from low-density microsomal membrane to plasma membrane was significantly increased in the orally Corosolic acid-treated mice when compared with that of the controls (Pb0.05) . Fukushima M demonstrated that Corosolic acid has an effect on lowering postchallenge plasma glucose levels in vivo in human. Corosolic acid treatment subjects showed lower glucose levels from 60 min until 120 min and reached statistical significance at 90 min. Although Corosolic acid was suggested to be a promising lead
compound for diabetes, its underlying mechanisms remain unknown.
Ahmad, F., Goldstein, B.J., 1995. Alterations in specific protein-tyrosine phosphatases accompany insulin resistance of streptozotocin diabetes. Metabolism 44, 1175–1184.
Ahmad, F., Azevedo, J.L., Cortright, R., Dohm, G.L., Goldstein, B.J., 1997a. Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. J. Clin. Invest. 100, 449–458.
Ahmad, F., Considine, R.V., Bauer, T.L., Ohannesian, J.P., Marco, C.C., Goldstein, B.J., 1997b. Improved sensitivity to insulin to obese subjects following weight loss is accompanied by reduced protein-tyrosine phosphatases in adipose tissue. Metabolism 46, 1140–1145.
American Diabetes Association, 2001. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26, 5S–20S.
Asante-Appiah, E., Kennedy, B.P., 2003. Protein tyrosine phosphatases: the quest for negative regulators of insulin action. Am. J. Physiol. Endocrinol. Metab. 284, 663–670.
Bleyle, L.A., Peng, Y., Ellis, C., Mooney, R.A., 1999. Dissociation of PTPase levels from their modulation of insulin receptor signal transduction. Cell Signal 11, 719–725.
Cavaghan, M.K., Ehrmann, D.A., Polonsky, K.S., 2000. Interaction between insulin resistance and insulin secretion in the development of glucose intolerance. J. Clin. Invest. 106, 329–333.
Cheng, A., Dube, N., Gu, F., Tremblay, M.L., 2002. Coordinated action of protein tyrosine phosphatases in insulin signal transduction. Eur. J. Biochem. 269, 1050–1059.